SG11202011228TA - Magl inhibitors - Google Patents
Magl inhibitorsInfo
- Publication number
- SG11202011228TA SG11202011228TA SG11202011228TA SG11202011228TA SG11202011228TA SG 11202011228T A SG11202011228T A SG 11202011228TA SG 11202011228T A SG11202011228T A SG 11202011228TA SG 11202011228T A SG11202011228T A SG 11202011228TA SG 11202011228T A SG11202011228T A SG 11202011228TA
- Authority
- SG
- Singapore
- Prior art keywords
- magl inhibitors
- magl
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Epoxy Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671985P | 2018-05-15 | 2018-05-15 | |
| PCT/US2019/032289 WO2019222266A1 (en) | 2018-05-15 | 2019-05-14 | Magl inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202011228TA true SG11202011228TA (en) | 2020-12-30 |
Family
ID=68534223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202011228TA SG11202011228TA (en) | 2018-05-15 | 2019-05-14 | Magl inhibitors |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US11332453B2 (en) |
| EP (1) | EP3793547A4 (en) |
| JP (1) | JP2021523200A (en) |
| KR (1) | KR20210010475A (en) |
| CN (1) | CN112088001A (en) |
| AR (1) | AR115092A1 (en) |
| AU (1) | AU2019271123A1 (en) |
| BR (1) | BR112020000863A2 (en) |
| CA (1) | CA3097063A1 (en) |
| CL (1) | CL2020002927A1 (en) |
| CO (1) | CO2020013550A2 (en) |
| CR (1) | CR20200545A (en) |
| DO (1) | DOP2020000207A (en) |
| EA (1) | EA202092586A1 (en) |
| GE (1) | GEP20227443B (en) |
| JO (1) | JOP20200276A1 (en) |
| MA (1) | MA52635A (en) |
| MX (1) | MX2020012158A (en) |
| NI (1) | NI202000080A (en) |
| PE (1) | PE20211385A1 (en) |
| PH (1) | PH12020551934A1 (en) |
| SG (1) | SG11202011228TA (en) |
| TW (1) | TW201946906A (en) |
| WO (1) | WO2019222266A1 (en) |
| ZA (1) | ZA202006327B (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE049690T2 (en) | 2012-01-06 | 2020-10-28 | Lundbeck La Jolla Research Center Inc | Carbamate compounds and methods of making and using same |
| JP7042804B2 (en) | 2016-09-19 | 2022-03-28 | ルンドベック ラ ホーヤ リサーチ センター，インク． | Piperazine carbamate, and how to make and use it |
| PL3793565T3 (en) | 2018-05-14 | 2022-05-02 | Gilead Sciences, Inc. | Mcl-1 inhibitors |
| CN112088001A (en) | 2018-05-15 | 2020-12-15 | 隆德贝克拉荷亚研究中心有限公司 | MAGL inhibitors |
| CN112638430B (en) | 2018-06-27 | 2023-05-16 | 豪夫迈·罗氏有限公司 | Radiolabeled cannabinoid receptor 2 ligands |
| MA54827A (en) * | 2019-01-25 | 2022-05-04 | H Lundbeck As | METHODS OF TREATING A DISEASE USING MAGL INHIBITORS |
| TWI778443B (en) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1 inhibitors |
| US20210147367A1 (en) * | 2019-11-15 | 2021-05-20 | Lundbeck La Jolla Research Center, Inc. | Crystalline forms of a magl inhibitor |
| CA3159951A1 (en) | 2019-11-26 | 2021-06-03 | Gilead Sciences, Inc. | Processes and intermediates for preparing mcl1 inhibitors |
| EP4139288A1 (en) | 2020-04-21 | 2023-03-01 | H. Lundbeck A/S | Synthesis of a monoacylglycerol lipase inhibitor |
| EP4198023A1 (en) | 2021-12-16 | 2023-06-21 | Basf Se | Pesticidally active thiosemicarbazone compounds |
| WO2023156402A1 (en) | 2022-02-17 | 2023-08-24 | Basf Se | Pesticidally active thiosemicarbazone compounds |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1593586A (en) | 1967-10-17 | 1970-06-01 | ||
| JPS6183073A (en) | 1984-10-01 | 1986-04-26 | Oki Electric Ind Co Ltd | Paper feed method of printing apparatus |
| WO1989011794A1 (en) | 1988-06-07 | 1989-12-14 | Rikagaku Kenkyusho | Plant growth inhibitor |
| WO1993011097A1 (en) | 1991-11-27 | 1993-06-10 | E.I. Du Pont De Nemours And Company | Herbicidal acylated amino-(phenyl- or pyridinyl- or thienyl-)-phenyl derivatives |
| EP0736047B1 (en) | 1993-12-22 | 1998-03-04 | Shell Internationale Researchmaatschappij B.V. | Process for preparing carbamates |
| JP2000500448A (en) | 1995-11-15 | 2000-01-18 | ゼネカ リミテッド | Herbicidal substituted pyrazole compounds |
| WO1998000408A1 (en) | 1996-07-02 | 1998-01-08 | Novartis Ag | N-phenylimino heterocyclic derivatives and their use as herbicides |
| RU2167150C2 (en) | 1998-03-25 | 2001-05-20 | Фокин Александр Васильевич | Polyfluoroalkyl-n-arylcarbamates showing antibacterial activity |
| WO2001025188A1 (en) | 1999-10-04 | 2001-04-12 | University Of Medicine And Dentistry Of New Jersey | Novel carbamates and ureas |
| EP1201298A1 (en) | 2000-10-24 | 2002-05-02 | Urea Casale S.A. | Carbamate condensation unit |
| DE10348022A1 (en) | 2003-10-15 | 2005-05-25 | Imtm Gmbh | New dipeptidyl peptidase IV inhibitors for the functional influence of different cells and for the treatment of immunological, inflammatory, neuronal and other diseases |
| FR2864080B1 (en) | 2003-12-23 | 2006-02-03 | Sanofi Synthelabo | 1-PIPERAZINE-AND-1-HOMOPIPERAZINE-CARBOXYLATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
| WO2005063698A1 (en) | 2003-12-31 | 2005-07-14 | Council Of Scientific & Industrial Research | Process for preparing carbamates |
| BRPI0507499A (en) | 2004-02-18 | 2007-07-24 | Astrazeneca Ab | compound or a pharmaceutically acceptable salt or hydrate thereof, pharmaceutical composition, use of the compound, and methods for treating mglur 5-mediated disorders and for inhibiting activation of mglur 5 receptors |
| CN101830899A (en) | 2004-12-23 | 2010-09-15 | 霍夫曼-拉罗奇有限公司 | Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents |
| ES2639621T3 (en) | 2004-12-30 | 2017-10-27 | Janssen Pharmaceutica N.V. | Phenylamide derivatives of 4- (benzyl) -piperazine-1-carboxylic acid and related compounds as modulators of fatty acid amide hydrolase (FAAH) for the treatment of anxiety, pain and other conditions |
| EP1948630A2 (en) | 2005-11-05 | 2008-07-30 | AstraZeneca AB | Novel compounds |
| JP2009523729A (en) | 2006-01-13 | 2009-06-25 | ピーティーシー セラピューティクス，インコーポレーテッド | Treatment method for hepatitis C |
| CN101679408B (en) | 2006-12-22 | 2016-04-27 | Astex治疗学有限公司 | As the bicyclic heterocycles of FGFR inhibitor |
| EP2124927A2 (en) | 2007-02-26 | 2009-12-02 | Kosan Biosciences Incorporated | Carbamate compounds |
| US8188098B2 (en) | 2008-05-19 | 2012-05-29 | Hoffmann-La Roche Inc. | GPR119 receptor agonists |
| AU2009270983A1 (en) | 2008-07-16 | 2010-01-21 | Schering Corporation | Bicyclic heterocycle derivatives and their use as GPCR modulators |
| US8772318B2 (en) | 2008-11-14 | 2014-07-08 | The Scripps Research Institute | Methods and compositions related to targeting monoacylglycerol lipase |
| CN102548558B (en) | 2009-03-23 | 2014-04-30 | Msdk.K.公司 | Novel aminopyridine derivatives having Aurora A selective inhibitory action |
| KR20110137831A (en) | 2009-04-22 | 2011-12-23 | 얀센 파마슈티카 엔.브이. | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
| UA107791C2 (en) | 2009-05-05 | 2015-02-25 | Dow Agrosciences Llc | Pesticidal compositions |
| TWI506011B (en) | 2009-11-03 | 2015-11-01 | Bayer Materialscience Ag | Fluorourethanes as additives in a photopolymer formulation |
| FR2960875B1 (en) | 2010-06-04 | 2012-12-28 | Sanofi Aventis | HEXAFLUOROISOPROPYL CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
| HUE049690T2 (en) * | 2012-01-06 | 2020-10-28 | Lundbeck La Jolla Research Center Inc | Carbamate compounds and methods of making and using same |
| CN104114543B (en) | 2012-01-06 | 2019-03-15 | 安吉奥斯医药品有限公司 | Therapeutical active compound and its application method |
| MX2014011134A (en) | 2012-03-19 | 2014-12-10 | Abide Therapeutics Inc | Carbamate compounds and of making and using same. |
| JP2014005245A (en) | 2012-06-26 | 2014-01-16 | Dainippon Sumitomo Pharma Co Ltd | Pharmaceutical composition containing bicyclic pyrimidine derivative |
| US9551036B2 (en) | 2013-02-25 | 2017-01-24 | Whitehead Institute For Biomedical Research | Metabolic gene mesenchymal signatures and uses thereof |
| WO2015003002A1 (en) | 2013-07-03 | 2015-01-08 | Abide Therapeutics, Inc. | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof |
| WO2016014975A2 (en) | 2014-07-25 | 2016-01-28 | Northeastern University | Urea/carbamates faah magl or dual faah/magl inhibitors and uses thereof |
| EP3271352B1 (en) | 2015-03-18 | 2021-05-12 | H. Lundbeck A/S | Piperazine carbamates and methods of making and using same |
| JP7042804B2 (en) | 2016-09-19 | 2022-03-28 | ルンドベック ラ ホーヤ リサーチ センター，インク． | Piperazine carbamate, and how to make and use it |
| JOP20190106A1 (en) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | Magl inhibitors |
| EA201991086A1 (en) * | 2016-11-16 | 2019-11-29 | MAGL CRYSTAL FORMS | |
| JOP20190105A1 (en) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | Magl inhibitors |
| EA202090296A1 (en) * | 2017-08-29 | 2020-08-03 | Лундбекк Ла-Хойя Рисерч Сентер, Инк. | SPIROCYCLIC COMPOUNDS AND METHODS FOR THEIR PREPARATION AND APPLICATION |
| CN112088001A (en) | 2018-05-15 | 2020-12-15 | 隆德贝克拉荷亚研究中心有限公司 | MAGL inhibitors |
| MA54827A (en) | 2019-01-25 | 2022-05-04 | H Lundbeck As | METHODS OF TREATING A DISEASE USING MAGL INHIBITORS |
-
2019
- 2019-05-14 CN CN201980031137.4A patent/CN112088001A/en active Pending
- 2019-05-14 TW TW108116518A patent/TW201946906A/en unknown
- 2019-05-14 KR KR1020207033709A patent/KR20210010475A/en not_active Application Discontinuation
- 2019-05-14 AR ARP190101283A patent/AR115092A1/en unknown
- 2019-05-14 CA CA3097063A patent/CA3097063A1/en active Pending
- 2019-05-14 AU AU2019271123A patent/AU2019271123A1/en not_active Abandoned
- 2019-05-14 GE GEAP201915479A patent/GEP20227443B/en unknown
- 2019-05-14 CR CR20200545A patent/CR20200545A/en unknown
- 2019-05-14 WO PCT/US2019/032289 patent/WO2019222266A1/en active Application Filing
- 2019-05-14 SG SG11202011228TA patent/SG11202011228TA/en unknown
- 2019-05-14 US US17/055,079 patent/US11332453B2/en active Active
- 2019-05-14 EA EA202092586A patent/EA202092586A1/en unknown
- 2019-05-14 MX MX2020012158A patent/MX2020012158A/en unknown
- 2019-05-14 JP JP2020564158A patent/JP2021523200A/en not_active Ceased
- 2019-05-14 BR BR112020000863-0A patent/BR112020000863A2/en not_active Application Discontinuation
- 2019-05-14 MA MA052635A patent/MA52635A/en unknown
- 2019-05-14 PE PE2020001853A patent/PE20211385A1/en unknown
- 2019-05-14 US US16/412,212 patent/US10570106B2/en not_active Expired - Fee Related
- 2019-05-14 JO JOP/2020/0276A patent/JOP20200276A1/en unknown
- 2019-05-14 EP EP19803143.7A patent/EP3793547A4/en not_active Withdrawn
-
2020
- 2020-01-10 US US16/739,642 patent/US11214557B2/en active Active
- 2020-10-12 ZA ZA2020/06327A patent/ZA202006327B/en unknown
- 2020-10-28 CO CONC2020/0013550A patent/CO2020013550A2/en unknown
- 2020-11-10 DO DO2020000207A patent/DOP2020000207A/en unknown
- 2020-11-11 CL CL2020002927A patent/CL2020002927A1/en unknown
- 2020-11-13 NI NI202000080A patent/NI202000080A/en unknown
- 2020-11-13 PH PH12020551934A patent/PH12020551934A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GEP20227443B (en) | 2022-11-25 |
| MA52635A (en) | 2021-03-24 |
| DOP2020000207A (en) | 2021-02-15 |
| CR20200545A (en) | 2020-12-17 |
| US20200148653A1 (en) | 2020-05-14 |
| AR115092A1 (en) | 2020-11-25 |
| ZA202006327B (en) | 2022-06-29 |
| CA3097063A1 (en) | 2019-11-21 |
| JP2021523200A (en) | 2021-09-02 |
| PE20211385A1 (en) | 2021-07-27 |
| EP3793547A1 (en) | 2021-03-24 |
| US20190352273A1 (en) | 2019-11-21 |
| EP3793547A4 (en) | 2021-11-17 |
| BR112020000863A2 (en) | 2020-12-08 |
| KR20210010475A (en) | 2021-01-27 |
| CO2020013550A2 (en) | 2020-11-10 |
| AU2019271123A1 (en) | 2020-11-26 |
| MX2020012158A (en) | 2021-01-29 |
| US20210206735A1 (en) | 2021-07-08 |
| CL2020002927A1 (en) | 2021-03-05 |
| CN112088001A (en) | 2020-12-15 |
| EA202092586A1 (en) | 2021-03-10 |
| WO2019222266A1 (en) | 2019-11-21 |
| TW201946906A (en) | 2019-12-16 |
| US10570106B2 (en) | 2020-02-25 |
| US11332453B2 (en) | 2022-05-17 |
| JOP20200276A1 (en) | 2020-11-02 |
| PH12020551934A1 (en) | 2021-06-21 |
| NI202000080A (en) | 2021-02-15 |
| US11214557B2 (en) | 2022-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283639A (en) | Kif18a inhibitors | |
| ZA202006327B (en) | Magl inhibitors | |
| IL276594A (en) | Fap inhibitor | |
| ME03759B (en) | Bromodomain inhibitors | |
| ZA201903100B (en) | Magl inhibitors | |
| IL266550A (en) | Magl inhibitors | |
| IL269196A (en) | Novel inhibitors | |
| ZA201903099B (en) | Magl inhibitors | |
| ZA201908070B (en) | Pyrazole magl inhibitors | |
| ZA201907136B (en) | Ip6k inhibitors | |
| IL276013A (en) | Pi4kiiibeta inhibitors | |
| IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| IL274550A (en) | Dopamine-b-hydroxylase inhibitors | |
| GB201812462D0 (en) | Inhibitors | |
| GB201804439D0 (en) | Dopamin-b-hydroxylase inhibitors | |
| GB201809939D0 (en) | Eastase inhibitor | |
| ZA201807614B (en) | Bromodomain inhibitors | |
| GB201721465D0 (en) | Inhibitors | |
| GB201720189D0 (en) | Dopamine-B-hydroxylase inhibitors |